Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Immunoscore
TIL
multispectral immunofluorescence
sTIL score
spatial heterogeneity
spatial statistics
tumor infiltrating lymphocytes
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
01
06
2023
accepted:
19
06
2023
medline:
29
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector-based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well-described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
514-532Subventions
Organisme : NCI NIH HHS
ID : P50 CA247749
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA225655
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA116201
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA254566
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA248226
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA239055
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257612
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA220581
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216579
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208236
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202752
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA249992
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA268207
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA269181
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA268287
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA225021
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA215109
Pays : United States
Organisme : NIBIB NIH HHS
ID : R43 EB028736
Pays : United States
Organisme : Cancer Research UK
ID : KCL-BCN-Q3
Pays : United Kingdom
Organisme : Cancer Research UK
ID : CRUK/07/012
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : R01 HL151277
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL158071
Pays : United States
Organisme : Cancer Research UK
ID : C45982/A21808
Pays : United Kingdom
Informations de copyright
© 2023 The Pathological Society of Great Britain and Ireland.
Références
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271.
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 2018; 391: 2128-2139.
Taube JM, Akturk G, Angelo M, et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer 2020; 8: e000155.
Tien TZ, Lee J, Lim JCT, et al. Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence (mIHC/IF). Histopathology 2021; 79: 139-159.
Toki MI, Merritt CR, Wong PF, et al. High-Plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling. Clin Cancer Res 2019; 25: 5503-5512.
Mi H, Gong C, Sulam J, et al. Digital pathology analysis quantifies spatial heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 immune markers in triple-negative breast cancer. Front Physiol 2020; 11: 583333.
Yuan Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harb Perspect Med 2016; 6: a026583.
Zormpas-Petridis K, Noguera R, Ivankovic DK, et al. SuperHistopath: a deep learning pipeline for mapping tumor heterogeneity on low-resolution whole-slide digital histopathology images. Front Oncol 2020; 10: 586292.
inForm User Manual Version 2.4.2 [Accessed 27 December 2019]. Available from: https://research.pathology.wisc.edu/wp-content/uploads/sites/510/2018/12/inFormUserManual_2_4_2_rev0.pdf.
Stack EC, Wang C, Roman KA, et al. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 2014; 70: 46-58.
Amgad M, Stovgaard ES, Balslev E, et al. Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-oncology Biomarker Working Group. NPJ Breast Cancer 2020; 6: 16.
Sanchez K, Kim I, Chun B, et al. Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer. Breast Cancer Res 2021; 23: 2.
Berry S, Giraldo NA, Green BF, et al. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science 2021; 372: eaba2609.
Nawaz S, Heindl A, Koelble K, et al. Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer. Mod Pathol 2015; 28: 766-777.
Francis K, Palsson BO. Effective intercellular communication distances are determined by the relative time constants for cyto/chemokine secretion and diffusion. Proc Natl Acad Sci U S A 1997; 94: 12258-12262.
Maley CC, Koelble K, Natrajan R, et al. An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res 2015; 17: 131.
Wilm F, Benz M, Bruns V, et al. Fast whole-slide cartography in colon cancer histology using superpixels and CNN classification. J Med Imaging (Bellingham) 2022; 9: 027501.
Turkki R, Linder N, Kovanen PE, et al. Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples. J Pathol Inform 2016; 7: 38.
Verghese G, Li M, Liu F, et al. Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies. J Pathol 2023; 260: 376-389.
Bivand RS, Pebesma E, Gomez-Rubio V. Applied Spatial Data Analysis with R. Springer: New York, NY, 2013.
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
Loi S, Winer E, Lipatov O, et al. Abstract PD5-03: relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). Cancer Res 2020; 80: PD5-03-PD05-03.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol 2020; 250: 667-684.
Cortes J, Cescon DW, Rugo HS, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. In ASCO Annual Meeting. Chicago, IL, 2020.
Scott M, Scorer P, Barker C, et al. Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol 2019; 30: iii4.
Feng Z, Bethmann D, Kappler M, et al. Multiparametric immune profiling in HPV-oral squamous cell cancer. JCI Insight 2017; 2: e93652.
Yuan Y. Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. J R Soc Interface 2015; 12: 20141153.
Van den Eynde M, Mlecnik B, Bindea G, et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell 2018; 34: e1013.
Etzioni R. Statistics for Health Data Science: An Organic Approach. Springer: Cham, Switzerland, 2021.
Khan AM, Yuan Y. Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. Sci Rep 2016; 6: 36231.
Yuan Y, Failmezger H, Rueda OM, et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci Transl Med 2012; 4: 157ra143.
Heindl A, Sestak I, Naidoo K, et al. Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER+ breast cancer. J Natl Cancer Inst 2018; 110: 10.1093/jnci/djx137.
AbdulJabbar K, Raza SEA, Rosenthal R, et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med 2020; 26: 1054-1062.
Corredor G, Wang X, Zhou Y, et al. Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer. Clin Cancer Res 2019; 25: 1526-1534.
Barua S, Fang P, Sharma A, et al. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer 2018; 117: 73-79.
Li X, Gruosso T, Zuo D, et al. Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer. Proc Natl Acad Sci U S A 2019; 116: 3678-3687.
Bose P, Brockton NT, Guggisberg K, et al. Fractal analysis of nuclear histology integrates tumor and stromal features into a single prognostic factor of the oral cancer microenvironment. BMC Cancer 2015; 15: 409.
Rasmusson A, Zilenaite D, Nestarenkaite A, et al. Immunogradient indicators for antitumor response assessment by automated tumor-stroma interface zone detection. Am J Pathol 2020; 190: 1309-1322.
Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 2019; 37: 559-569.
Balkenhol MC, Ciompi F, Swiderska-Chadaj Z, et al. Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics. Breast 2021; 56: 78-87.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382: 810-821.
Gartrell-Corrado RD, Chen AX, Rizk EM, et al. Linking transcriptomic and imaging data defines features of a favorable tumor immune microenvironment and identifies a combination biomarker for primary melanoma. Cancer Res 2020; 80: 1078-1087.
Fassler DJ, Torre-Healy LA, Gupta R, et al. Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression. Cancer 2022; 14: 2148.
Apetoh L, Smyth MJ, Drake CG, et al. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Onco Targets Ther 2015; 4: e998538.
Danenberg E, Bardwell H, Zanotelli VRT, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet 2022; 54: 660-669.
Wang Y, Wang YG, Hu C, et al. Cell graph neural networks enable the precise prediction of patient survival in gastric cancer. NPJ Precis Oncol 2022; 6: 45.
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 2019; 25: 1706-1714.
Berben L, Wildiers H, Marcelis L, et al. Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software. Histopathology 2020; 77: 79-91.
Ho DJ, Yarlagadda DVK, D'Alfonso TM, et al. Deep multi-magnification networks for multi-class breast cancer image segmentation. Comput Med Imaging Graph 2021; 88: 101866.
Wershof E, Park D, Barry DJ, et al. A FIJI macro for quantifying pattern in extracellular matrix. Life Sci Alliance 2021; 4: e202000880.
Vanhersecke L, Bougouin A, Crombe A, et al. Standardized pathology screening of mature tertiary lymphoid structures in cancers. Lab Invest 2023; 103: 100063.
Vanhersecke L, Brunet M, Guégan JP, et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2021; 2: 794-802.
Halama N, Zoernig I, Berthel A, et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 2016; 29: 587-601.
Halama N, Michel S, Kloor M, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011; 71: 5670-5677.
Berthel A, Zoernig I, Valous NA, et al. Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival. Oncoimmunology 2017; 6: e1286436.
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50.
Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 2016; 4: 59.
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol 2019; 5: 74-82.
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30: 1541-1557.
Swisher SK, Wu Y, Castaneda CA, et al. Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the International TILs Working Group. Ann Surg Oncol 2016; 23: 2242-2248.
TILs in breast cancer [Accessed 4 August 2020]. Available from: https://www.tilsinbreastcancer.org/.
Brown JR, Wimberly H, Lannin DR, et al. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2014; 20: 5995-6005.
Yaghoobi V, Martinez-Morilla S, Liu Y, et al. Advances in quantitative immunohistochemistry and their contribution to breast cancer. Expert Rev Mol Diagn 2020; 20: 509-522.
Sun P, He J, Chao X, et al. A computational tumor-infiltrating lymphocyte assessment method comparable with visual reporting guidelines for triple-negative breast cancer. EBioMedicine 2021; 70: 103492.
Kos Z, Roblin E, Kim RS, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer 2020; 6: 17.
Chen HX, Song M, Maecker HT, et al. Network for biomarker immunoprofiling for cancer immunotherapy: cancer immune monitoring and analysis centers and cancer immunologic data commons (CIMAC-CIDC). Clin Cancer Res 2021; 27: 5038-5048.
Chou M, Illa-Bochaca I, Minxi B, et al. Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma. Mod Pathol 2021; 34: 562-571.
Acs B, Ahmed FS, Gupta S, et al. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. Nat Commun 2019; 10: 5440.
Saldanha G, Flatman K, Teo KW, et al. A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring. Am J Surg Pathol 2017; 41: 906-914.
Moore MR, Friesner ID, Rizk EM, et al. Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. Sci Rep 2021; 11: 2809.
Thagaard J, Broeckx G, Page DB, et al. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the International Immuno-oncology Biomarker Working Group. J Pathol 2023; 250: 498-513.
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964.